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Background
Chloroquine (CQ) resistance in P. falciparum is strongly
linked to mutations in the gene pfcrt that gives rise to
the protein, PfCRT (P. falciparum chloroquine resis-
tance transporter), located in the parasite’sd i g e s t i v e
vacuole (DV) membrane [1]. In CQ resistant (CQR)
strains, accumulation of CQ is reduced in the DV due
to increased efflux [2], relative to CQ sensitive (CQS)
malaria.
Method
We have developed a class of molecules, termed Reversed
Chloroquine compounds (RCQs), that are hybrids made
up of a chloroquine (CQ) like moiety, and a chemosensi-
tizer (Reversal Agent, RA) against CQR in malaria [3].
Subsequent structure-activity relationship (SAR) work
showed the RCQ molecular design to be very flexible.
Thus, a large variety of RCQ molecules has been con-
structed that retain the in vitro efficacy against P. falci-
parum malaria [4].
Results
The RCQ molecules have been shown to have low- to
even sub-nanomolar in vitro IC50 values against both
CQR and CQS malaria strains. Here we report on an
expanded set of RCQ entities. A subset of these drug
candidates has been tested in mouse models of malaria,
and found to be capable of reducing the parasite burden
to below detectable limits; being able to cure by the oral
route. Furthermore, RCQ molecules are shown to have
enhanced uptake into CQR parasites. Both cytotoxicity
and acute toxicity in mice are favorable, as is Ames eva-
luation of mutagenicity. hERG binding SAR shows that
variation in the RCQ structure can be used to minimize
potential cardiotoxicity issues.
Conclusion
The RCQ approach remains a strong contender to exceed
the advantages that CQ brought to malaria chemotherapy
for nearly half a century, before being thwarted by
resistance.
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